Want to see SBFM full AI Analyst Report?
Sunshine Biopharma (SBFM) Ratios
495 Followers
Sunshine Biopharma Ratios
SBFM's free cash flow for Q2 2026 was $-912.85K. For the 2026 fiscal year, SBFM's free cash flow was increased by $5.13K and operating cash flow was $-917.98K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.17 | 4.11 | 4.48 | 3.94 | 24.07 |
| Quick Ratio | 2.08 | 2.33 | 3.45 | 3.47 | 22.91 |
| Cash Ratio | 1.42 | 1.53 | 2.93 | 3.15 | 22.42 |
| Solvency Ratio | -0.80 | -0.70 | -0.71 | -3.37 | -6.24 |
| Operating Cash Flow Ratio | -0.83 | -1.98 | -1.58 | -0.76 | -20.05 |
| Short-Term Operating Cash Flow Coverage | -24.72 | 0.00 | 0.00 | -42.66 | 0.00 |
| Net Current Asset Value | $ 19.81M | $ 18.91M | $ 18.75M | $ 19.39M | $ 204.60K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.02 | 0.03 | 0.86 |
| Debt-to-Equity Ratio | 0.04 | 0.04 | 0.03 | 0.04 | 8.98 |
| Debt-to-Capital Ratio | 0.03 | 0.04 | 0.03 | 0.03 | 0.90 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.90 |
| Financial Leverage Ratio | 1.31 | 1.30 | 1.29 | 1.37 | 10.41 |
| Debt Service Coverage Ratio | -26.17 | -558.68 | -30.73 | -164.25 | -36.78 |
| Interest Coverage Ratio | 0.00 | -662.43 | -34.85 | -685.10 | -7.42 |
| Debt to Market Cap | 0.04 | 0.00 | 0.00 | 0.01 | 0.25 |
| Interest Debt Per Share | 39.09 | 13.70 | 65.35 | 106.02 | 1706.60 |
| Net Debt to EBITDA | 1.48 | 1.70 | 4.09 | 0.80 | 0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 32.84% | 30.60% | 34.61% | 39.05% | 48.42% |
| EBIT Margin | -16.40% | -15.37% | -16.49% | -609.11% | -5300.62% |
| EBITDA Margin | -15.48% | -14.73% | -15.87% | -608.54% | -5294.93% |
| Operating Profit Margin | -12.34% | -16.67% | -19.86% | -621.28% | -1068.18% |
| Pretax Profit Margin | -16.40% | -15.40% | -17.06% | -610.01% | -5444.21% |
| Net Profit Margin | -16.46% | -14.72% | -18.70% | -615.37% | -5444.21% |
| Continuous Operations Profit Margin | -16.46% | -14.72% | -18.70% | -615.37% | -5444.21% |
| Net Income Per EBT | 100.36% | 95.63% | 109.61% | 100.88% | 100.00% |
| EBT Per EBIT | 132.93% | 92.38% | 85.91% | 98.19% | 509.67% |
| Return on Assets (ROA) | -19.87% | -16.80% | -16.48% | -90.52% | -564.53% |
| Return on Equity (ROE) | -25.94% | -21.85% | -21.25% | -123.66% | -5875.41% |
| Return on Capital Employed (ROCE) | -18.95% | -23.97% | -21.95% | -119.40% | -115.55% |
| Return on Invested Capital (ROIC) | -18.78% | -22.73% | -21.84% | -118.75% | -115.55% |
| Return on Tangible Assets | -21.20% | -18.64% | -17.40% | -92.96% | -564.53% |
| Earnings Yield | -116.86% | -243.87% | -68.21% | -275.28% | -162.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.49 | 9.02 | 9.44 | 2.27 | 29.29 |
| Payables Turnover | 4.30 | 4.37 | 6.09 | 0.95 | 2.74 |
| Inventory Turnover | 1.81 | 2.15 | 2.75 | 0.81 | 1.12 |
| Fixed Asset Turnover | 27.17 | 23.53 | 23.79 | 3.76 | 32.35 |
| Asset Turnover | 1.21 | 1.14 | 0.88 | 0.15 | 0.10 |
| Working Capital Turnover Ratio | 1.81 | 1.79 | 1.21 | 0.39 | 0.22 |
| Cash Conversion Cycle | 151.67 | 126.97 | 111.63 | 227.72 | 206.71 |
| Days of Sales Outstanding | 34.78 | 40.49 | 38.67 | 160.59 | 12.46 |
| Days of Inventory Outstanding | 201.67 | 170.07 | 132.87 | 453.31 | 327.27 |
| Days of Payables Outstanding | 84.79 | 83.59 | 59.90 | 386.19 | 133.02 |
| Operating Cycle | 236.46 | 210.56 | 171.53 | 613.91 | 339.73 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -256.49 | -178.57 | -721.34 | -691.48 | -1400.56 |
| Free Cash Flow Per Share | -264.88 | -211.64 | -786.12 | -731.67 | -1400.56 |
| Dividend Paid and CapEx Coverage Ratio | -30.55 | -5.40 | -11.13 | -17.21 | 0.00 |
| Capital Expenditure Coverage Ratio | -30.55 | -5.40 | -11.13 | -17.21 | 0.00 |
| Operating Cash Flow Coverage Ratio | -6.56 | -13.16 | -13.34 | -6.86 | -0.96 |
| Operating Cash Flow to Sales Ratio | -0.15 | -0.36 | -0.36 | -1.21 | -8.01 |
| Free Cash Flow Yield | -107.68% | -705.48% | -144.77% | -57.16% | -23.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.85 | -0.41 | -1.47 | -0.36 | -0.61 |
| Price-to-Sales (P/S) Ratio | 0.14 | 0.06 | 0.27 | 2.24 | 33.42 |
| Price-to-Book (P/B) Ratio | 0.22 | 0.09 | 0.31 | 0.45 | 36.06 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.93 | -0.14 | -0.69 | -1.75 | -4.17 |
| Price-to-Operating Cash Flow Ratio | -0.96 | -0.17 | -0.75 | -1.85 | -4.17 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.00 | 0.02 | 0.01 | -0.00 |
| Enterprise Value Multiple | 0.57 | 1.29 | 2.36 | 0.43 | -0.62 |
| Enterprise Value | -3.20M | -6.63M | -9.03M | -11.35M | 7.49M |
| EV to EBITDA | 0.57 | 1.29 | 2.36 | 0.43 | -0.62 |
| EV to Sales | -0.09 | -0.19 | -0.37 | -2.61 | 32.78 |
| EV to Free Cash Flow | 0.58 | 0.45 | 0.94 | 2.04 | -4.09 |
| EV to Operating Cash Flow | 0.60 | 0.53 | 1.03 | 2.16 | -4.09 |
| Tangible Book Value Per Share | 1017.52 | 291.86 | 1624.59 | 2747.13 | 162.07 |
| Shareholders’ Equity Per Share | 1108.42 | 334.89 | 1743.31 | 2849.48 | 162.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.04 | -0.10 | -0.01 | 0.00 |
| Revenue Per Share | 1746.74 | 496.96 | 1980.52 | 572.60 | 174.91 |
| Net Income Per Share | -287.48 | -73.16 | -370.41 | -3523.58 | -9522.21 |
| Tax Burden | 1.00 | 0.96 | 1.10 | 1.01 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.03 | 1.00 | 1.03 |
| Research & Development to Revenue | 0.02 | 0.03 | 0.08 | 0.19 | 2.94 |
| SG&A to Revenue | 0.54 | 0.43 | 0.42 | 2.05 | 8.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.02 |
| Income Quality | 0.89 | 2.44 | 1.95 | 0.20 | 0.15 |
Currency in USD
